Townsend T, Razanskaite V, Dodd S, et al. - Since anti‐tumour necrosis factor (TNF) agents are effective in Crohn disease but some patients lose response and need alternative biologic therapy, researchers compared the efficacy of ustekinumab and vedolizumab in anti‐TNF‐refractory Crohn disease over 12 months. Participants in the study were patients starting ustekinumab or vedolizumab for anti‐TNF‐refractory Crohn's disease with minimum follow‐up of 12 months. Eighty-five patients starting vedolizumab and 45 commencing ustekinumab were included. Rates of steroid‐free and clinical remission were significantly higher among ustekinumab‐treated patients in an unadjusted model. Ustekinumab seemed more effective in treating anti‐TNF‐refractory Crohn disease and more patients continued with therapy.